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DNA aneuploidy in early breast cancer
GL Ottesen', IJ Christensen2, JK Larsen2, GB Kerndrup', B Hansen' and JA Andersen'
'Institute ofPathology, Odense University Hospital, 5000 Odense C; 2The Finsen Laboratory, Rigshospitalet, 2100 Copenhagen 0,
Denmark.
Summary High-resolution flow cytometric (FCM) DNA analysis was performed on 148 unfixed, frozen tissue
samples from four groups of early breast cancers: invasive carcinomas (ICs) with predominance of carcinoma
in situ (DCIS) (group I), small clinical cancers < 15 mm (group II), node-negative, clinical cancers (group III)
and small screening-detected cancers < 15 mm (group IV). The median tumour size was 12 mm. The aim of
the study was to support, with a larger sample, our recent findings with respect to DNA ploidy pattern in the
selected group of ICs with predominance of DCIS (group I). Similar results to this group were found for both
the small clinical cancers and the node-negative cancers, with respect to frequency of DNA aneuploidy (79%
and 90%), DNA index (DI) distribution, intratumoral DNA heterogeneity and S-phase fraction. A high
frequency of DNA hyperdiploid clones was found, in particular related to highly differentiated tumours. A
significant difference was found compared with the screening-detected cancers, which were characterised by a
much lower frequency of DNA aneuploid samples (49%) and may represent a biologically specific group of
low-malignant, slowly growing tumours. Associations were shown between histological grade and DI sub-
classes, and between lymph node status and DNA diploidy/aneuploidy, whereas DI was not correlated with
tumour size. The DNA ploidy findings in this series of early cancers are concordant to our own results from
preinvasive lesions as well as those reported from series of more advanced cancers.
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Numerous studies on DNA analysis of breast carcinomas
have been published during the last 10 years, in particular
dealing with node-negative cancers in order to investigate the
possible prognostic value of DNA index (DI) and S-phase
fraction (SPF). This is not the aim of the present study. Our
area of interest is the early developmental stages of breast
cancer, i.e. the premalignant stage ofductal carcinoma in situ
(DCIS) and its relation to early invasive carcinoma (IC). As
the purpose was a basic investigation, we found it essential to
obtain precise results employing high resolution DNA
measurements and we therefore performed the flow cyto-
metric (FCM)-DNA analysis exclusively on unfixed, frozen
tissue.
Recently, we investigated the DNA distribution in a series
of 41 clinical DCIS lesions by flow cytometry (Ottesen et al.,
1995a) and found results comparable with those from a
Danish study of421 cases ofnode-negative IC (Balslev et al.,
1994) with respect to both frequency of DNA aneuploidy,
DNA heterogeneity, DI distribution and SPF. The two
studies were comparable with respect to methodology. The
results indicated that major DNA changes, as measured by
FCM, were established already at the preinvasive stage of
carcinogenesis.
While this agreement applied to the overall results for
DCIS and IC, it might not necessarily reflect the develop-
ment in the individual case. In order to investigate this
subject further, we therefore selected a series of breast
cancers with predominance of DCIS (the B2b group, accord-
ing to WHO, 1981) for comparison between the DCIS and
the IC component within the individual lesion (Ottesen et al.,
1995b). Identical clones were found in the two components.
The only difference was the finding of additional DNA
hyperdiploid peaks in the IC component, not present in the
corresponding DCIS component. These made up 39% of the
clones, a higher frequency than reported in other studies of
IC. This result might be explained by the high resolution in
our analysis, with a median coefficient of variation (CV) of
less than 2%. Another possibility might be that the selected
material of carcinomas with predominance of DCIS, repres-
enting less than 10% of all breast carcinomas, was not
representative of breast cancer in general.
The purpose of the present study is to investigate further
the DNA ploidy pattern in a larger series of early breast
cancers. Since it is not possible to define biologically early
cancers in clinical terms, we chose to study small cancers
with diameter < 15mm. The introduction in November 1993
of mammography screening in our hospital enabled us to
study screening-detected breast cancers as well as clinical
cases from the period before screening. We also included a
series of node-negative ICs from the period before screening.
Finally, the IC cases from the carcinomas with predominance
of DCIS were included for comparison. The study includes a
comparison of the DNA ploidy results with the most import-
ant histopathological parameters
Materials and methods
The material consists of 148 cases from four groups of breast
carcinomas. Since the individual case may belong to two or
even three groups, the sum of the cases in the four groups
exceeds 148. This overlapping does not influence the results
for the individual groups, but cases represented more than
once are excluded for statistical comparison of the groups.
Group I Ductal carcinomas with predominance of DCIS.
Of the 48 cases in the previous study (Ottesen et
al., 1995b), 33 cases from which DNA analysis
was performed from the IC component were
included in the present study. These cases were
diagnosed from August 1985 to April 1994.
Group II Clinical carcinomas from the time period before
mammography screening, with a diameter <
15mm; 52 cases from 50 patients (since two
patients had two tumours) were diagnosed from
October 1992 to October 1993.
Group III Node-negative carcinomas from the time period
before mammography screening; 50 cases were
diagnosed from January 1993 to October 1993.
Group IV Carcinomas with a diameter < 15mm, detected by
mammography screening from the first prev-
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alence round; 41 cases from 39 patients (since
two patients had two tumours) were diagnosed
from November 1993 to September 1994. -, .
Groups I, II and III thus comprise clinically detected
cancers, while group IV comprises screening-detected cancers.
Overlapping cases are found particularly in groups II and o
III, in which 18 cases are included in both series. Also 10 of
the 33 cases from group I are included in the other series:
four cases in group II, three cases in both II and III, and . , _ o
three cases in IV.
All cases come from one department of Pathology (Odense R k
University Hospital). The criterion for inclusion was the
presence of unfixed, frozen tissue. Because of this criterion,
29 cases from the consecutive series for group II, III and IV
were not included, mainly because of small tumour size Z E. t as en C
(median size 6.5 mm). . X
All cases were histopathologically reviewed and classified _ ',
according to tumour size, histological type (WHO, 1981),
r histological grade (WHO, 1968) and lymph node status.
o z M
Flow cytometry O 4 o a o
Only unfixed, frozen tissue samples were used for flow . E
cytometry. The IC diagnosis was confirmed by a frozen
section of the tissue sample before aspiration and/or conven-
tional histological examination of the formalin-fixed tissue
remnants after aspiration. From all samples, touch preparat- @ X'oo_enC
ions and cytological slides from the cell suspensions were also
inspected to ensure that a sufficient number of tumour cells
was present.
The frozen tissue blocks were prepared for FCM as X
previously described (Ottesen et al., 1995a), according to the o
propidium iodide (PI) staining method of Vindel0v et al. 0 4 _ 0 r 00
(1983). For the flow cytometric measurements a Becton
Dickinson FACSort was used. PI fluorescence was measured
as the pulse area at 564-606 nm (FL2-A, 10 000 counts, 1024
channels resolution). . z
For a parallel methodological study, an additional frozen
sample from 56 cases (27 cases from group III and 29 cases X 0 % o I.,
from group IV) was disaggregated in a Medimachine, CON- o m
' , _ o
SUL for comparison with fine-needle aspiration. The FCM
DNA analysis results in these 56 cases are thus based on two
samples. The detailed methodological study is described in a
co
separate paper (Ottesen et al., 1995c). z
All samples with poor model fit to the histogram or other 1 : SR't So
potential problems, in particular DNA near-diploid clones,
were reanalysed. X %
0E
Interpretation ofDNA histograms and statistics
The DNA fluorescence histograms were analysed as prev-
iously described (Ottesen et al., 1995a) using a model des- % _
cribed by Vindel0v and Christensen (1990).
A clone is defined to be DNA diploid, if the estimated DI 0 X
is within the 95% confidence limit as calculated from the O
- N
lymphocyte standards, + 3.3%. This definition leads to the °%
following seven arbitrary subclasses: the DNA diploid inter-
val was set as 0.967<DI < 1.033, and the DNA tetraploid o. er-. O- 00
interval consequently was 1.934<DI < 2.066. In between, a E
DNA triploid class was defined as 1.451 <DI < 1.550.
Hypodiploid, hyperdiploid, hypotetraploid and hypertetra-
ploid DI classes were then defined as being less than, between
or greater than these classes. 00
DNA ploidy heterogeneity is defined as the occurrence of
two or more non-diploid clones. As the samples contain a
varying number of benign cells (epithelial, stromal, endo- 8 E thelial, inflammatory) a diploid G1peak will nearly always be ° E E
present. Only in a purely diploid histogram was the tumour v E -
classified as DNA diploid, whereas in a histogram with a Z E 0 v/ o v
non-diploid peak in addition to the diploid peak it is not . v possible by single parameter analysis to determine the
presence of a diploid tumour clone among the normal cells. 8 X .0
Evaluable S-phases were chosen from samples which *u v
(1) are purely DNA diploid; oDNAaneuploidy Inearlybmrst cancer %V GLOttesen etal
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(2) are DNA aneuploid with DI> 1.4 comprising at least
25% of the total sample and with no other sub-
populations confounding the S-phase distribution; or
(3) are DNA aneuploid with only small (<15%) sub-
populations interfering with the S-phase distribution.
Visual inspection of forward light scatter versus PI
fluorescence was used to control for artifacts, especially for
cases with near-diploid peaks. In addition, in some cases the
time sequence of the measurements in the list mode files was
inspected to ensure that no shifts had occurred in the PI
fluorescence as a function of time.
a
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Tests for association were done using the chi-square test.
All statistical tests were performed on datasets with each case
represented only once. Cases represented in more than one
group are excluded for statistical analysis.
Results
The median CV of the trout erythrocyte (TRBC) reference
peak was 1.2% (0.9-1.5) and of the DNA diploid GI peak
1.5% (1.2-3.1).
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Figure 1 The figure shows the DI estimates for each of the four groups of breast cancers: (a) Group I, carcinomas with
predominance of DCIS; (b) Group II, clinical cancers < 15 mm; (c) Group III, node-negative cancers; (d) Group IV, screening-
detected cancers < 15 mm. @, samples that are included only in one group; 0, samples that are included in two groups (identical
markings are found in both groups); A, samples that are included in three groups, with identical markings in all three groups.
Confidence limits for DNA diploid and DNA tetraploid subclasses are indicated.
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Figure 2 DNA distribution of the 205 clones from the 148 cases.
The columns with DNA index 1.00 and 2.00 include only clones
defined as DNA diploid (= DNA diploid cases) and DNA tetra-
ploid respectively.
The DI estimates of all cases for each of the four groups
are shown in detail Figure 1, while Table I shows the class-
ification into DNA diploid cases, DNA tetraploid cases, and
cases with at least one DNA aneuploid clone. The DNA
aneuploid cases are further divided into DNA subclasses.
Owing to the presence of multiple DNA non-diploid clones
in several histograms, the number of clones detected is higher
than the number of samples. A total of 205 clones were
found in the 148 samples. Because of the overlapping of the
four groups, the total number is less than the sum of the four
figures.
In the four groups, DNA diploidy was found in 6-51%,
DNA tetraploidy in 0-6% and DNA aneuploidy in 49-90%
of the cases (Table I). A test for independence indicated a
significant difference (P<0.0001) between the screening
group and the groups of clinical cancers, the screening group
having most DNA diploid cases.
Among the DNA aneuploid cases only (Table I, right), the
distribution of the DIs in all four groups shows a similar
pattern with maxima in the DNA hyperdiploid and hypo-
tetraploid subclasses. Among the total number of clones
within each of the four groups, the frequency of DNA hyper-
diploid clones is 39%, 35%, 30% and 20% respectively.
The bimodal distribution of DIs for all 148 cases also
appears from Figures 1 and 2. Figure 2 demonstrates the
predominance of DNA near-diploid clones within the DNA
hyperdiploid subclass. One sample with DI 1.03 and three
samples with DI 0.97 were classified as DNA non-diploid
because of the coincidence with a second peak with DI closer
to 1. An example is given in Figure 3e.
Intratumoral DNA heterogeneity, as defined by occurrence
of multiple DNA non-diploid clones, was found in 46/148
samples (31%): in 11/33 (33%) in group I, in 18/52 (35%) in
II, in 21/50 (42%) in III and in 7/41 (17%) in IV. Two clones
were found in 37 samples, three clones in seven samples and
four clones in two samples.
The addition of a second sample (using the Medimachine)
resulted in changes in DNA ploidy classification in 10 of the
56 cases. Compared with the first sample, the second sample
detected in group III a DNA hyperdiploid clone in a DNA
diploid case, a DNA hypotetraploid clone in a DNA tetra-
DNAaneuploidy in early breast cancer
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ploid case, a DNA hypotetraploid (two cases) and a DNA
hyperdiploid clone (one case) in cases already classified as
DNA aneuploid. In group IV, a DNA hypodiploid (one case)
and a DNA hyperdiploid clone (three cases) were detected in
DNA diploid cases and in one case an additional DNA
hypotetraploid clone was found. Examples of histograms are
given in Figure 3.
S-phasefraction
Accurate estimation of SPF was considered essential and
therefore only 78 samples-34 DNA diploid and 44 DNA
aneuploid-were included, fulfilling the criteria for evaluation.
DNA diploid samples had a median SPF of 5% (2-13),
compared to 11% (2-31) for DNA aneuploid sub-
populations. Testing for difference between DNA diploid and
DNA aneuploid SPFs showed a significantly higher value
(P<0.0001) for the latter. If the SPFs of small clinical
cancers are compared with those from the screening cancers,
a significant difference (P = 0.04) between DNA aneuploid
SPFs in the two groups, 10% and 4% respectively, was
demonstrated using analysis of variance. No difference
between the DNA diploid SPFs could be demonstrated
between the two groups.
Histopathology
The histological data and age of the patients are shown in
Table II. The median size of the tumour was 12 mm (5-35)
for the total material. For the individual groups, the median
size for groups I, II and IV was comparable, being 11 mm,
12 mm and 10 mm, respectively while group III tumours, the
node-negative cancers, were larger with a median size of
19mm (7-35).
Nodal status is based on microscopy of median 13 axillary
lymph nodes (1-36). This number is similar in all four
groups. In seven cases the lymph node status is unknown,
since axillary dissection was not performed, mainly because
of the age of the patient. The frequency of lymph node
metastases is 56% in group I, compared with 32% in group
II and 26% in group IV.
With respect to histological grade, groups I, II and IV
were dominated by grade I tumours, while in group III a
more even distribution was seen. Among the small tumours
in groups I, II and IV, the distribution of histological grade
was similar in groups II and IV, but was significantly
different to group I (P= 0.02).
No association was found between lymph node status and
histological grade (P = 0.69, chi-square test) or tumour size
(P= 0.07, rank sum test). Also no association was found
between histological grade and tumour size in groups I, II
and IV, while in group III grade I tumours were smaller
(median 12 mm), compared with grade II and III (both with
median of 20 mm).
Correlation ofDNA ploidy to histopathology
The correlation between DNA ploidy and histological grade
is shown in Table III. High histological grade was associated
with DNA diploidy (P=0.002) and DNA hyperdiploidy
(P= 0.03), whereas an inverse association was found with
DNA hypotetraploidy (P<0.0001). With respect to lymph
node status, a significant association was shown between
node-negative tumours and DNA diploidy, compared with
DNA aneuploidy (P =0.003), and between node-positive
tumours and DNA hypertetraploidy (P= 0.002) (data not
shown). No correlation was shown between DI and tumour
size.
Discussion
The present study is a direct consequence of our two
previous studies of the DNA distribution in clinical DCIS
lesions and in breast carcinomas with predominance ofDNAaneuploidy inearly breast cancer
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Table II Histopathological classification and age for the four groups of
breast carcinoma
Invasive carcinoma
I II III IV
Median age (years) 53 (38-76) 58 (39-85) 62 (39-88) 61 (50-70)
Median size (mm) 11 (7-20) 12 (5-15) 19 (7-35) 10 (6-15)
Node status N+ 18 N+ 16 N+ 10
N-14 N-32 N-50 N-29
?(-)] ? 4 ? 2
Histology
Ductal carcinoma 33 46 44 36
Grade I 16 30 14 24
Grade II 9 11 12 11
Grade III 8 5 18 1
Lobular carcinoma 4 4 5
Mucinous 2 1
Medullary 1
aAxillary dissection was not performed.
TableIII Correlation betweenDNAploidyandhistologicalgrade. TheDNAaneuploidsamplesarefurthercharacterisedby thenumberofclonesin
the DNA subclasses (right part of the table).
DNA aneuploid clones in DI subclasses
Histological Number of DNA diploid DNA tetraploid DNA aneuploid Hypodi- Hyperdi- Tri- Hypotetra- Tetra- Hypertetra-
grade cases cases (%) cases (%) cases (%) ploid ploid ploid ploid ploid ploid
I 66 22 (33) 0 (0) 44 (67) 10 36 0 10 3 5
II 39 4 (10) 3 (8) 32 (82) 6 13 7 20 0 2
III 28 2 (7) 2 (7) 24 (86) 0 5 5 20 4 7
DCIS, selected for comparison between the DCIS and the IC
component within the individual lesion. No differences could
be shown for DCIS lesions with or without invasion. An
almost identical DNA ploidy pattern was found in corres-
ponding DCIS and IC samples, except for the additional
finding in the IC component of DNA hyperdiploid clones, in
particular among highly differentiated tumours. The results
indicated that the characteristic DNA distribution of IC was
present already at the preinvasive stage of the carcinogenetic
process and that major DNA changes, as detected by FCM,
may not on their own be important for invasiveness, but that
this biologically crucial event may be caused by very limited
genomic changes. This is in agreement with the comments
from the DNA Cytometry Consensus Conference (Hedley,
1993) that significant chromosomal aberrations, that cannot
be disclosed by FCM, may be more relevant to biological
aggression than the gross alterations in chromosome content
associated with an abnormal histogram.
The present study was undertaken to test whether our
results from the selected series of carcinomas with pre-
dominance of DCIS are representative and our conclusions
from the previous study are applicable in general. Evidently,
we were particularly interested in very early breast cancers.
Since the study had a biological and not a prognostic goal,
we preferred to select groups of cancers rather than to inves-
tigate an unselected series. Therefore specific groups of so-
called early cancers with supposed different biology were
selected: small cancers irrespective of nodal status, and node-
negative cancers.
We considered it essential to perform the FCM-DNA
analysis on unfixed, frozen tissue in order to obtain high-
resolution histograms with precise DI estimation and the
ability to discriminate closely related cell clones in DNA
heterogeneous lesions. Although comparative studies of
unfixed and fixed tissue have shown a high degree of accor-
dance (Frierson, 1988; Kallioniemi, 1988a; Alanen et al.,
1989; Zalupski et al., 1993), the mean CVs of analyses in
unfixed tissue reported in these studies were above 3%, com-
pared with a median CV of 1.5% in our series.
The results from the present study indicate that the DNA
ploidy findings in the carcinomas with predominance of
DCIS are representative for clinical cancers, since similar
results were found in the two other clinical groups, i.e. the
node-negative group and the small clinical cancers. On the
contrary, a significant difference was found to the screening
group, which had a high frequency (51%) of DNA diploid
samples, in accordance with results from both first (Kall-
ioniemi et al., 1988b) and later rounds of screening (Hatschek
et al., 1989). A high frequency of DNA diploid tumours was
also found in the studies of Eriksson et al. (1994) of screen-
ing cancers < 10 mm and of Uyterlinde et al. (1991) of
screening cancers with a mean tumour size of 16.5 mm. We
also compared our DNA ploidy results to those from larger
series of breast cancers, which included cancers at more
advanced stages according to the TNM classification (Ewers
et al., 1989; Beerman et al., 1990; Stal et al., 1992; Balslev et
al., 1994). It appears that DNA aneuploidy is found as
frequently in cancers at early stage, as compared with later
stages.
The occurrence of DNA hyperdiploid clones showed the
same pattern in the three clinical groups (I, II and III), with
frequencies from 30-39%. These figures are high in com-
parison with results from studies of FCM-DNA analysis of
breast cancers in the literature. Few studies specify the fre-
quency of DNA hyperdiploid clones. Only Cornelisse et al.
(1983) found a similar value of 29% (13 hyperdiploid clones
among 45 stemlines), while lower frequencies were found in
other studies (Beerman et al., 1990; Uyterlinde et al., 1991;
Fern0 et al., 1992). In the Danish study (Balslev et al., 1994),
the frequency of hyperdiploid clones was about 20%. The
high frequency of DNA hyperdiploid clones in our material
may, first of all, be explained by the high DNA measurement
resolution, as expressed by the low CVs that allow discrimin-
ation of closely related clones. It is of course important to
exclude the possibility that the near-diploid peaks are not
true clones, but artifacts. Indications of true clones are that
the clones are reproducible by reanalysis, they appear as
symmetrical, narrow peaks with low CV, and an additional,
strictly diploid peak is present in all but two histograms. In
all cases the forward light scatter was inspected and in cases
of doubt the time sequence of measurements in the list mode
datafiles was used for supplementary evaluation of the his-
togram. On this technical basis we consider it substantially
verified that the DNA hyperdiploid peaks represent trueDNAaneuploidy in early breastcancer
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Figure 3 DNA fluorescence histograms from samples of breast carcinomas. The two first peaks in each histogram are the chicken
and trout erythrocyte internal standards respectively. The histograms are shown as step curves with the fitted model superimposed
in the inserted histograms in a, d, e and f. (a) From screening-detected cancer (group IV), tumour size 7 mm, node-positive,
histological grade II. DNA aneuploid and heterogeneous with DIs 1.04, 1.91 and 2.20. CV = 1.6%. The insert shows the
hypotetraploid/tetraploid/hypertetraploid region from channel 325 to 450, showing two aneuploid subpopulations in addition to
two G2 + M peaks. (b) From small, clinical cancer (group II), tumour size 15 mm, node-positive, histological grade III. DNA
diploid with DI 1.00. CV = 1.2%. (c) From screening-detected cancer (group IV), tumour size 8 mm, node-positive, histological
grade I. DNA diploid with DI 1.02. CV = 1.2%. (d) From cancer, belonging to both the cancers with predominance of DCIS and
the screening group (groups I + IV), tumour size 10 mm, node-negative, histological grade I. DNA aneuploid and heterogeneous
with three hyperdiploid clones with DIs 1.11, 1.23 and 1.33. CV = 3.0%. The insert shows the diploid/hyperdiploid region from
channel 175 to 280. (e) From node-negative cancer (group III), tumour size 22 mm, node-negative, histological grade I. DNA
hypodiploid with DI 0.97, CV = 1.2%. Although the DI is in the diploid range, the sample is classified as DNA hypodiploid due to
the coincidence with a second peak with DI. 1.01. The insert shows the hypodiploid/diploid/hyperdiploid region from channel 175
to 230. (f) From small clinical cancer (group II), tumour size 8 mm, node-negative, invasive lobular carcinoma. DNA aneuploid
with two hyperdiploid clones with DIs 1.06 and 1.10, CV = 1.4%. The insert shows the diploid/hyperdiploid region from channel
185 to 240.
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clones, as supported also by the biological findings. Thus, the
DNA hyperdiploid clones are in particular present in histo-
logical grade I tumours, similar to the findings in the carc-
inomas with predominance of DCIS. The slight DNA
hyperploidy found by FCM may correspond to some of the
subsets of breast carcinomas that by chromosomal analysis
have been found to be characterised by only minimal devia-
tions from the normal 46,XX karyotype (Pandis et al., 1995).
Examples of hyperdiploid clones are given in Figure 3a, d
and f.
Intratumoral DNA heterogeneity showed agreement bet-
ween the clinical groups, with frequencies of 35% and 42%,
compared with 33% in carcinomas with predominance of
DCIS and 37% in the series of pure DCIS (Ottesen et al.,
1995a). In the Danish study of 421 node-negative car-
cinomas, with a median tumour size of 25 mm (Balslev et al.,
1994), a frequency of 24% was found. This study is com-
parable with ours, because unfixed, frozen tissue samples
were prepared and measured by flow cytometry in the same
way, and the data were interpreted by the same statistician
(IJC). Results from previous studies raised the possibility
that heterogeneity might be less in tumours from patients
with early cancers (Beerman et al., 1991). Our results indicate
that heterogeneity is present with the same frequency in
carcinomas of smaller size and even in the preinvasive stage
of DCIS.
The second sample analysed in 56 cases from groups III
and IV did not influence the DNA ploidy pattern to a great
extent. Although a bias in the estimation of the frequency of
DNA ploidy is present, this does not in any way invalidate
our results. The reason for these differences could in most
cases be intratumoral DNA heterogeneity. In some cases, the
probably explanation is a lower CV in the second sample.
The exclusion of the second sample would have resulted in a
larger difference between the clinical and the screening
groups.
We found that DNA diploid clones had a significantly
lower SPF in comparison with DNA aneuploid clones. This
is in agreement with results from the literature (Kallioniemi
et al., 1988b; Hatschek et al., 1989; Ferno et al., 1992; Stal et
al., 1992; Balslev et al., 1994). Like the other DNA
parameters, the SPF values of the IC groups are similar to
those of DCIS lesions (Ottesen et al., 1995a). The figure of
5% in the DNA diploid ICs is similar to that found in
benign samples included in the DCIS study. This indicates a
very low growth rate for these tumours. We were able to
demonstrate a significant difference in SPF between the
screening group and the small clinical cancers, however, only
for the DNA aneuploid subpopulations. In comparison,
Kallioniemi et al. (1988b) found lower SPF in the screening
group compared with the control group, for the DNA dip-
loid as well as the DNA aneuploid subpopulations, whereas
Hatschek (1989) did not find any differences.
The histopathological classification demonstrated a lack of
relationship between traditional parameters in the present
series of carcinomas. No association could be proven
between lymph node status and tumour size or histological
grade. With respect to DNA ploidy, an association was
shown between lymph node status and DNA diploidy/
aneuploidy and also between histological grade and sub-
classes of DI, whereas DI was not correlated with tumour
size.
In conclusion, the present study shows
(1) that the DNA ploidy data of the selected group of
ductal carcinomas with predominance of DCIS were
similar to those of the two clinical groups, i.e. the small
clinical cancers and the node-negative cancers; and
(2) that they differed significantly from those of the
screening-detected cancers.
These may represent a biologically specific group of low-
malignant, slowly growing tumours. In addition, the DNA
findings in the clinical cancers, as regards both DNA ploidy,
DI distribution, frequency of intratumoral heterogeneity and
SPF, are in agreement with the findings in node-negative
breast cancers of larger size, as well as in preinvasive DCIS
lesions. The only difference to the DCIS lesions was the
additional presence, particularly in highly differentiated
cancers, of DNA near-diploid clones that may possibly be
related to invasion.
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